TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$149.5 Million

TransMedics Group, Inc

Follow-on Offering

Bookrunner, August 2022

TransMedics Group, Inc

TransMedics Group, Inc. (“TransMedics” or “the Company”) is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. TransMedics developed the Organ Care System, or the OCS, to replace a decades-old standard of care that the Company believes is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. The innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.